| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/02/2004 | US20040171538 Anticoagulants and their uses |
| 09/02/2004 | US20040171530 Polypeptides containing cysteine and tryptophan |
| 09/02/2004 | US20040171524 Glycoconjugate that is enzyme conjugated to carbohydrate which binds to a lectin |
| 09/02/2004 | US20040171520 Melanocortin receptor-specific peptidomimetics |
| 09/02/2004 | US20040171123 fusion protein of an antibody that binds to human epidermal growth factor receptor-2 (HER2) and albumin with long shelf-life; stabilizing therapeutic proteins such as antibodies by conjugating them to albumin |
| 09/02/2004 | US20040171122 Gm-csf and/or defensin protein expression regulators in epithelial cells comprising ets transcription factor or gene encoding the same |
| 09/02/2004 | US20040171117 Anti-RANK ligand monoclonal antibodies useful in treatment of RANK ligand mediated disorders |
| 09/02/2004 | US20040171111 Polypeptide of a p53 protein-specific murin a/t-cell receptor, nucleic acids coding therefor and use thereof |
| 09/02/2004 | US20040171033 Comprises modified nucleotide sequences for use in gene expression inhibition, viral defense, transposon silencing and treatment of metabolic disorders; antisense agents |
| 09/02/2004 | US20040170999 Nuclear hormone receptor ligand binding domain |
| 09/02/2004 | US20040170980 Molecules capable of binding to telomere and the like and method with the use of the same |
| 09/02/2004 | US20040170973 DNA encoding the human serine protease EOS |
| 09/02/2004 | US20040170969 GRF2 binding proteins and applications thereof |
| 09/02/2004 | US20040170653 recognised by CD8-positive cytotoxic T-lymphocytes as a peptide antigen and causes a CTL-induced lysis and/or apoptosis of tumor or leukemia cell; has the amino acid sequence LLGDLFGV, which corresponds to the amino acid positions 81 to 88 of the hdm2 proto-oncoprotein |
| 09/02/2004 | US20040170649 uses optimal solvent systems such that the lipid envelope around the viral particle is dissolved while the viral particle remains intact; autologous vaccines |
| 09/02/2004 | US20040170620 Selected antibody compositions for binding to aminophospholipids |
| 09/02/2004 | US20040170618 antagonists bind to a recognized target (e.g., a receptor); the enzyme component of the chimera then degrades the target resulting in a reduction of activity of the target and release of the chimeric molecule, which is then free to attack and degrade another target molecule. |
| 09/02/2004 | US20040170613 Compositions and methods for liver growth and liver protection |
| 09/02/2004 | US20040170611 culturing an autologous or allogenic dermal papilla cell in the presence of a Wnt polypeptide or a fragment or analog thereof, and grafting the cultured cell onto the skin |
| 09/02/2004 | US20040170573 Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route |
| 09/02/2004 | US20040170569 Dosage forms that rapidly produces peak plasma concentrations; heating a thin layer of the drug on a solid support to form a vapor; and passing air through the heated vapor to produce aerosol particles having less than 10% drug degradation products |
| 09/02/2004 | US20040170560 Liposome confining prodrug, radioactive materials; multilayer; storage stability; antiinflammatory agents; infection therapy; antitumor agents imaging for diagnosis |
| 09/02/2004 | CA2518313A1 Medicament comprising noble metal fineparticles |
| 09/02/2004 | CA2518311A1 Superoxide anion scavenger |
| 09/02/2004 | CA2516945A1 Therapeutic agent for spinal cord injury comprising interleukin-6 antagonist |
| 09/02/2004 | CA2516339A1 Dispersing agent for sustained-release preparation |
| 09/02/2004 | CA2515251A1 Blood-vessel-growth promoter |
| 09/01/2004 | EP1452600A1 Receptor and nucleic acid molecule encoding said receptor |
| 09/01/2004 | EP1452594A1 Inducer for differentiation of embryo stem cells into ectodermal cells, method of obtaining the same and use thereof |
| 09/01/2004 | EP1452587A1 Stem cells originating in salivary duet epithelial cells and use thereof |
| 09/01/2004 | EP1452530A1 Azole compound and medicinal use thereof |
| 09/01/2004 | EP1452528A1 Xanthine oxidase inhibitors |
| 09/01/2004 | EP1452527A1 Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation |
| 09/01/2004 | EP1452526A1 Indole compound and medicinal use thereof |
| 09/01/2004 | EP1452491A1 Titanium-group metal containing high-performance water, and its producing method and apparatus |
| 09/01/2004 | EP1452254A1 Preparation of metallic nanoparticle with shell-crosslinked micelle as mold |
| 09/01/2004 | EP1452205A1 Uses of keratinocyte growth factor-2 |
| 09/01/2004 | EP1452182A1 Angiogenesis drugs |
| 09/01/2004 | EP1451856A2 Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells |
| 09/01/2004 | EP1451368A2 Single nucleotide polymorphisms in gh-1 |
| 09/01/2004 | EP1451337A2 Nogo receptor-mediated blockade of axonal growth |
| 09/01/2004 | EP1451307A2 Type 2 cytokine receptor and nucleic acids encoding same |
| 09/01/2004 | EP1451300A2 Methods and compositions for the use of stromal cells to support embryonic and adult stem cells |
| 09/01/2004 | EP1451222A2 Novel proteins with il-6 inhibiting activity |
| 09/01/2004 | EP1451218A2 Methods for the treatment and prognosis of leukemia and other cancer types |
| 09/01/2004 | EP1451210A2 Hepta-, octa- and nonapeptides having antiangiogenic activity |
| 09/01/2004 | EP1451202A1 Aryl fused azapolycyclic compounds |
| 09/01/2004 | EP1451197A1 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo- 3.2.2 nonane derivatives, preparation and therapeutic use thereof |
| 09/01/2004 | EP1451193A1 Podophyllotoxins as antiproliferative agents |
| 09/01/2004 | EP1451192A1 Novel crystalline compound |
| 09/01/2004 | EP1451191A1 Thioether substituted imidazoquinolines |
| 09/01/2004 | EP1451190A1 Triazolo(4,3-a)pyrido(2,3-d)pyrimidin-5-one derivatives, compositions containing same, preparation method and use thereof |
| 09/01/2004 | EP1451188A1 4-(oxadiazol-3-yl)-1,4-diazabicyclo 3.2.2]-nonane derivatives, preparation and therapeutic use thereof |
| 09/01/2004 | EP1451187A1 Amide substituted imidazopyridines |
| 09/01/2004 | EP1451186A2 Urea substituted imidazopyridines |
| 09/01/2004 | EP1451185A1 Indole-2-carboxamides as factor xa inhibitors |
| 09/01/2004 | EP1451184A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451182A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451177A1 Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine |
| 09/01/2004 | EP1451176A2 Benzazepine derivatives and their use as 5-ht ligands |
| 09/01/2004 | EP1451174A2 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers |
| 09/01/2004 | EP1451167A1 Phenylalkynes |
| 09/01/2004 | EP1451164A2 Amide derivatives having improved solubility |
| 09/01/2004 | EP1451162A1 Substituted diphenyl heterocycles useful for treating hcv infection |
| 09/01/2004 | EP1451158A1 Therapeutic quinoline compounds with 5-ht-antagonistic properties |
| 09/01/2004 | EP1451157A1 Therapeutic quinolone compounds with 5-ht-antagonistic properties |
| 09/01/2004 | EP1451156A1 4-aminoquinoline compounds |
| 09/01/2004 | EP1451154A2 Inhibitors of cytosolic phospholipase a2 |
| 09/01/2004 | EP1450862A1 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 09/01/2004 | EP1450849A2 Methods of treating endometreosis |
| 09/01/2004 | EP1450847A2 Apo2 ligand/trail formulations |
| 09/01/2004 | EP1450840A2 Di-, tri,- and tetra-peptides having antiangiogenic activity |
| 09/01/2004 | EP1450839A2 Method of treating estrogen responsive breast cancer |
| 09/01/2004 | EP1450837A2 Interleukin-1 receptors in the treatment of diseases |
| 09/01/2004 | EP1450836A2 Method for short-term and long-term drug dosimetry |
| 09/01/2004 | EP1450828A2 In situ immunization |
| 09/01/2004 | EP1450826A1 Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium |
| 09/01/2004 | EP1450822A2 Polymeric thiol-linked prodrugs |
| 09/01/2004 | EP1450821A1 Immunostimulatory oligodeoxynucleotides |
| 09/01/2004 | EP1450816A2 Method of treating disorder related to high cholesterol concentration |
| 09/01/2004 | EP1450814A2 Methods of inhibiting metastases |
| 09/01/2004 | EP1450811A2 2-aryl pyrrolopyrimidines for a1 and a3 receptors |
| 09/01/2004 | EP1450809A2 Nucleosides preparation thereof and use as inhibitors of rna viral polymerases |
| 09/01/2004 | EP1450807A1 Method of treating depression with delta receptor agonist compounds |
| 09/01/2004 | EP1450805A1 Method for the treatment of overactive bladder |
| 09/01/2004 | EP1450801A2 2-aminoquinoline compounds |
| 09/01/2004 | EP1450799A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| 09/01/2004 | EP1450797A1 Benzothiazole derivatives |
| 09/01/2004 | EP1450795A1 Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease |
| 09/01/2004 | EP1450794A1 Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents |
| 09/01/2004 | EP1450782A1 Use of alkanoyl l-carnitine for the treatment of erectile dysfunction |
| 09/01/2004 | EP1450781A1 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| 09/01/2004 | EP1450780A1 Use of 4-oxobutanoic acid derivatives in the treatment of inflammation |
| 09/01/2004 | EP1450779A1 Method for treating autoimmune diseases |
| 09/01/2004 | EP1450778A2 Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases |
| 09/01/2004 | EP1450775A2 Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections |
| 09/01/2004 | EP1450770A2 Pharmaceutical composition comprising a 5ht1 receptor agonist |
| 09/01/2004 | EP1450769A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process |
| 09/01/2004 | EP1450762A1 Novel formulation |
| 09/01/2004 | EP1450751A2 Nanoparticle delivery vehicle |